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It started at school. I went to a girl’s school, Alexandra School
and College in Dublin, where both our physics teacher and our
chemistry teacher had PhDs and were excellent and inspirational
teachers. And in a very early science exam I got 99/100. Some-
how from then on it seemed clear to everyone (but also to me)
that I would be a scientist. The high mark was of course a woeful
way of measuring the skills I would later need, as at that stage a
good memory would sufﬁce. Those who know me well will share
my exasperation that I obviously wasted some useful brain cells
in those early years as my ability to remember facts is now rather
embarrassing, and to remember faces or names even more so.
There was never a question of whether or not I would go to
University, just what subject I would study. My father had qual-
iﬁed in medicine and dentistry, but I never fancied medicine; I
was not at all sure I could either cause pain (in retrospect an
odd way of viewing a healing profession) or cope with people
vomiting. I was right about this latter concern, as I later found
out when taken on tours of TB wards with my stomach heaving
as people generated and spat out sputum. Anyway, there
seemed to be general agreement that Natural Sciences in
Trinity College Dublin was where I was heading and as is usu-
ally the case, I had a marvelous time at university.
Natural Sciences in Trinity was a 4 y honors course, where you
started out with physics, chemistry and biology and gradually
reduced subjects to end up with one subject in your ﬁnal year. Ini-
tially I was certain I wanted to be a chemist. But by the second
year I had moved to Chemistry, Biochemistry and Microbiology,
by year 3 it was Biochemistry and Microbiology and in the end I
got a degree in Microbiology. Some part of this was that I was not
happy with equations or too much maths, and less so with the
Krebs cycle or too many pathways. But much more than this was
the fact that I could see the bacteria. Somehow this made them
real in a way molecules could never be. We also had some out-
standing microbiology lecturers, who were young, and passionate
about their subjects, including the recently appointed Tim Foster,
and Mary McLoughlin who taught us immunology. For my
Finals, I tried to do a project on bacterial chemotaxis which
completely failed to work, and then unexpectedly (as I was
considered to be a safe Upper Second class degree) narrowly got a
First. I am grateful that they explained this so narrow margin so
clearly to me, to prevent me having any delusions for the future.
Just as whether to go to university was never the question, just
what to study, there was no question of whether I would do a
PhD, just in what and where. I could have decided to research
antibiotic resistance and bacterial plasmids, and have wondered
since how my life would have gone if I had, as this was the early
days of bacterial genetics – but I applied for a dullish microbiol-
ogy job in Kent. And as I had another application pending with
someone in London, and as Finals loomed and my options for
trips to the UK would be limited I rang John Greenspan who was
advertising the London-based job. The result was an informal
interview and a paid research assistant post allowing me to do a
PhD working on autoimmunity, on Sjogren’s syndrome in man
and its NZB/NZW model. The post was in a Pathology Depart-
ment in the Royal Dental Hospital of London.
I loved London. I felt I had ﬁnally got to where things hap-
pened, and with new found friends and Stephen who became my
life partner enjoyed art, music, theater, Indian food and more.
The science was stimulating too. This was the dark ages for
human T cells. Martin Raff had made one anti-monkey thymus
antibody that seemed to react with human T cells, but while
staining macrophages for lysosomal enzymes I noticed than
many of the T cells had dot-like staining too.1 Those T cells had
lysosomes, something that as we all moved into multiparameter
ﬂow analysis had been forgotten- but they must be still there.
John Greenspan gave me supervision and freedom, until he left
for San Francisco half way through my PhD, thus giving me
unlimited freedom – but leaving me with the promise of advice
from John Playfair at the Middlesex Hospital Medical School.
That led to a postdoctoral position with John Playfair work-
ing on vaccines for malaria, my ﬁrst introduction to vaccines.
Those were great years. Ivan Roitt’s Immunology Department
at the Middlesex was large, energetic, and stimulating. I trav-
eled to international immunology meetings, although never to
anywhere where there was malaria. It was an absorbing and fas-
cinating time, although in retrospect we were more interested
in how immunity to malaria worked than in trying to design a
vaccine. I had my name on my one and only Nature paper, I
found that malaria parasites were killed by hydrogen peroxide,2
and my work began to be noticed. However, by then I was in
my early thirties and just as for those at the same stage now,
the future looked insecure.
So when someone said that Keith McAdam was returning
from Boston to set up a new Department of Clinical Tropical
Medicine at the London School of Hygiene & Tropical Medi-
cine, where I had already had some enjoyable collaborations,
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I went to see him. And just as for John Greenspan, he had a job
to offer me, although he wanted someone to work on human T
cells in leprosy. This was a great period and good fun too, with
Keith’s charisma and the optimism of a new and truly multi-
disciplinary department. I lost a lot of ground, years probably,
as I knew painfully little about T cells (other than that they had
a few lysosomes) and nothing about leprosy. But within the
year, I had been allocated a Pakistani clinician PhD student,
Rumina Hasan, and went to visit her at the Aga Khan
University (AKU) in Karachi, Pakistan.
That ﬁrst visit to Pakistan was a real turning point. I saw the
human disease, leprosy. It was hard to study as Mycobacterium
leprae would not grow and the patients were reluctant to donate
blood no matter how few teaspoons you said the large syringe
held. But just as for those bacteria I had seen down the micro-
scope, leprosy was real. When I returned, my father, a wise man,
commented that I would have been changed by this experience. I
was, having been taken out of my cosy environment to the reality
of life in low and middle income countries. We analyzed T cell
responses to newly produced recombinant leprosy antigens, and
cloned T cells. We demonstrated what seemed to be leprosy
transmission in an old folks’ home in the UK.3 I discovered what
it meant to really collaborate with someone, working more closely
with Rabia Hussain at AKU than with anyone else before or since.
Over the subsequent years I was seduced from leprosy into
tuberculosis, which led to studies in Portugal and The Gambia -
including the role of mycobacteria-speciﬁc CD8 T cells4 - and
was then challenged by Paul Fine to explain why BCG gave vari-
able protection. Working with Paul and the Karonga Prevention
Study (KPS), also changed me. Epidemiologists are different
from laboratory immunologists in many ways, but doing immu-
nology in 500 or more BCG vaccinated individuals allows you to
see differences far more clearly than when you do small-scale
immunology on groups of 10–15 donors. We exploited a diluted
whole blood assay developed by Rosemary Weir for her PhD
project on leprosy in Nepal5 and compared how BCG induced
immunity in Malawi compared with the UK.6,7 This marked my
move into human vaccines. Despite the big push to develop new
TB vaccines, we had never properly understood why BCG gave
variable protection, and still don’t. To directly compare
BCG-induced protective efﬁcacy in the UK and Malawi would
have required studies much larger than ours, but we did show
that the same vaccine, given initially to adolescents and young
adults, and then to infants, induces different immune signatures
in Africa and the UK.6,7 We have continued to explore how envi-
ronment impacts immunity in Uganda with Alison Elliott’s
group, and in the UK, now led by Steven Smith in my group,8
and how co-infections with helminths and co-morbidities like
diabetes impact on immune signatures. This all matters as many
of the new TB vaccines would be given after a priming vaccina-
tion with BCG – and any factors affecting how BCG works might
also affect other live mycobacterial vaccines, or the boosting seen
post-BCG with antigens delivered by vaccines or with adjuvant.
The move into vaccine biomarkers also connected us to a
European community working on TB vaccines. We have been
partners in European consortia including TBVAC, NEW-
TBVAC and TBVAC2020, managed by the TuBerculosis Vac-
cine initiative, TBVI (www.tbvi.eu), which has brought links to
scientists including Helen McShane in Oxford and Tom
Ottenhoff in Leiden and in consortia that aimed to support
cross-disease vaccine development such as TRANSVAC and
EURIPRED. We were partners in a Bill and Melinda
Gates –funded Grand Challenges 6–74 project led by Stefan
Kaufmann in Berlin, that helped identify a gene expression pro-
ﬁle that predicts those who are silently progressing to TB dis-
ease,9 and studies led by Gerhard Walzl at Stellenbosch
University and Jackie Cliff at LSHTM have demonstrated gene
expression changes in TB, including during TB treatment.10
This connectivity has been another game-changer. My research
family became worldwide, and all the better for this, although
the TB Centre (http://tb.lshtm.ac.uk/) and the Vaccine Centre
(http://vaccines.lshtm.ac.uk/) are now bringing stronger cross-
faculty links at LSHTM. Biomarkers remain our key interest as
having a protective biosignature to measure would really facili-
tate the development of new TB vaccines.
People have often asked why I have remained at LSHTM.
Because it became my life and perhaps too much so. Because it
never made me feel unequal as a woman scientist, or that not
being clinically qualiﬁed was an issue. For other reasons too,
including a wealth of opportunities to collaborate internation-
ally. Over time, as well as Pakistan and Malawi I have had the
Nepal years, the Gambia years, the Portugal years, the Mexico
years – and these days my main links are with Entebbe, Cape
Town, and Seoul. Apparently as a child, when I asked could we
go somewhere different the day after visiting one of the best
beaches south of Dublin, my father said “if I was taken to Para-
dise one day, I would want to go somewhere else the next day.”
LSHTM has certainly given me plenty of opportunities to
travel. To work with people based in a country also enables you
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to see that country in a very special way. To work in a ﬁeld that
never, never stops changing means you never get bored. I am
lucky that through all this I have had an incredibly supportive
partner who never tells me not to go or not to work, but skil-
fully books the odd tickets for the theater and meanwhile does
all the shopping and cooking.
I also stay because LSHTM has given me, someone
always looking for the next change, a wealth of different
roles in a one-world environment. I have been in charge of
the research degree program, an MSc course, a department
and a faculty, and performed other roles (currently as Spe-
cial Advisor on Overseas Programmes in Africa) as well as
carrying out research. But it is more than that. The LSHTM
has a mission, to “improve health worldwide.” Despite the
RAEs, the REFs, the QAAs, Brexit and more, we have a col-
lective core motivation. Partly because there is still so much
disease. But also because a succession of special students
keep coming. They come from afﬂuent Europe, the UK or
the US, but also from Asia, Africa and South America.
They have often given up much to get to us, and more
while they stay with us. We boast that education changes
lives, but our students often miss long periods with their
children, and pay large sums to come to London. So of
course we want to help them achieve their potential. Espe-
cially when so often they are what re-energises and moti-
vates us, and they then bring us further connections and
opportunities.
What strikes me most as I write this is that it is, and was
always, the people that matter most. Vaccine research is not
performed by individuals working in isolation - we need teams
and consortia to design, test and improve vaccines. We also
need teams to identify correlates of protection for TB vaccines,
which will work in the messy real world where we highly vari-
able humans have co-infections and co-morbidities. Working
together is productive and rewarding. We do not yet have a
new TB vaccine, nor biomarkers of protection, but collectively,
we are making progress.
Some special people brought me into science, gave me oppor-
tunities at key points throughout my career and continue to help
me enormously - I thank all those named and not named.
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